ArticleInternational journal of clinical oncology2026
Benefits of PARP inhibitor rechallenge in patients with platinum-sensitive recurrent ovarian cancer previously treated with a PARP inhibitor: a multicenter retrospective study.
Ami Jo et al.PubMed ↗Publisher ↗
No numbers read from the abstract.